Vol. 2 No. 9 (2022): September
Reimbursement Reviews

Zanubrutinib (Brukinsa)

Published September 21, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses zanubrutinib (Brukinsa) 80 mg capsules; oral.
  • Indication: For the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.